Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 19 | 2015 | 1011 | 3.940 |
Why?
|
| Cognition | 14 | 2018 | 1277 | 2.330 |
Why?
|
| Alzheimer Disease | 19 | 2018 | 1942 | 2.310 |
Why?
|
| Apolipoprotein E4 | 7 | 2018 | 227 | 2.180 |
Why?
|
| Population Surveillance | 7 | 2015 | 116 | 1.980 |
Why?
|
| Cognitive Dysfunction | 8 | 2018 | 938 | 1.930 |
Why?
|
| Stroke | 6 | 2016 | 293 | 1.770 |
Why?
|
| Aging | 11 | 2017 | 1593 | 1.450 |
Why?
|
| Longitudinal Studies | 18 | 2018 | 1442 | 1.430 |
Why?
|
| Aged | 48 | 2018 | 9448 | 1.420 |
Why?
|
| Female | 51 | 2018 | 16197 | 1.230 |
Why?
|
| Male | 48 | 2018 | 15621 | 1.220 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2017 | 441 | 1.170 |
Why?
|
| Genome-Wide Association Study | 14 | 2017 | 301 | 1.140 |
Why?
|
| Aged, 80 and over | 33 | 2018 | 4851 | 1.100 |
Why?
|
| Humans | 70 | 2018 | 29337 | 1.100 |
Why?
|
| Chicago | 15 | 2018 | 865 | 1.070 |
Why?
|
| Depression | 6 | 2014 | 465 | 1.030 |
Why?
|
| Polymorphism, Single Nucleotide | 16 | 2017 | 306 | 1.030 |
Why?
|
| Risk Factors | 15 | 2018 | 2443 | 0.870 |
Why?
|
| Cognitive Aging | 3 | 2018 | 81 | 0.850 |
Why?
|
| Biological Products | 2 | 2013 | 40 | 0.850 |
Why?
|
| Incidence | 8 | 2018 | 756 | 0.820 |
Why?
|
| Neuropsychological Tests | 10 | 2018 | 1251 | 0.780 |
Why?
|
| Stress, Psychological | 5 | 2013 | 246 | 0.760 |
Why?
|
| United States | 11 | 2018 | 2333 | 0.760 |
Why?
|
| Hospitalization | 2 | 2013 | 317 | 0.730 |
Why?
|
| Memory, Episodic | 3 | 2017 | 116 | 0.720 |
Why?
|
| Heterocyclic Compounds | 3 | 2015 | 11 | 0.700 |
Why?
|
| Dementia | 3 | 2017 | 521 | 0.700 |
Why?
|
| Apolipoproteins E | 2 | 2017 | 230 | 0.670 |
Why?
|
| Follow-Up Studies | 9 | 2017 | 1830 | 0.630 |
Why?
|
| Geriatric Assessment | 5 | 2015 | 219 | 0.620 |
Why?
|
| Activities of Daily Living | 4 | 2015 | 501 | 0.620 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 14 | 0.620 |
Why?
|
| Disease Progression | 8 | 2017 | 787 | 0.610 |
Why?
|
| Art | 1 | 2016 | 3 | 0.600 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 67 | 0.600 |
Why?
|
| Mortality | 2 | 2016 | 86 | 0.590 |
Why?
|
| Music | 1 | 2016 | 19 | 0.580 |
Why?
|
| Diabetes Complications | 1 | 2016 | 64 | 0.570 |
Why?
|
| Reading | 1 | 2016 | 40 | 0.560 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 148 | 0.550 |
Why?
|
| Prospective Studies | 9 | 2016 | 1811 | 0.540 |
Why?
|
| Time Factors | 7 | 2017 | 1616 | 0.530 |
Why?
|
| Health Planning | 1 | 2015 | 5 | 0.520 |
Why?
|
| Body Mass Index | 2 | 2015 | 428 | 0.520 |
Why?
|
| Residence Characteristics | 3 | 2015 | 216 | 0.520 |
Why?
|
| Social Support | 2 | 2013 | 185 | 0.520 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 168 | 0.510 |
Why?
|
| Genetic Loci | 5 | 2016 | 61 | 0.510 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 53 | 0.510 |
Why?
|
| Drug Monitoring | 1 | 2014 | 24 | 0.510 |
Why?
|
| Depressive Disorder | 1 | 2015 | 187 | 0.500 |
Why?
|
| Erythrocyte Indices | 1 | 2014 | 5 | 0.500 |
Why?
|
| Mobility Limitation | 1 | 2015 | 97 | 0.500 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 34 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 51 | 0.490 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 18 | 0.490 |
Why?
|
| Disability Evaluation | 3 | 2013 | 327 | 0.490 |
Why?
|
| Sleep | 1 | 2017 | 313 | 0.490 |
Why?
|
| Memantine | 1 | 2014 | 13 | 0.480 |
Why?
|
| Vitamin E | 1 | 2014 | 27 | 0.480 |
Why?
|
| Dopamine Agents | 1 | 2014 | 40 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 200 | 0.470 |
Why?
|
| Carbolines | 1 | 2013 | 2 | 0.470 |
Why?
|
| Algorithms | 3 | 2015 | 400 | 0.470 |
Why?
|
| Diterpenes | 1 | 2013 | 9 | 0.470 |
Why?
|
| Antioxidants | 1 | 2014 | 56 | 0.470 |
Why?
|
| Censuses | 1 | 2013 | 6 | 0.460 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 402 | 0.460 |
Why?
|
| Carboxylic Acids | 1 | 2012 | 1 | 0.460 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 218 | 0.460 |
Why?
|
| Imides | 1 | 2012 | 2 | 0.460 |
Why?
|
| Tetracycline | 1 | 2012 | 4 | 0.450 |
Why?
|
| Isoxazoles | 1 | 2012 | 16 | 0.450 |
Why?
|
| Anemia | 1 | 2014 | 97 | 0.440 |
Why?
|
| Urban Population | 1 | 2013 | 143 | 0.440 |
Why?
|
| Imines | 1 | 2012 | 1 | 0.440 |
Why?
|
| Alkaloids | 1 | 2012 | 5 | 0.440 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2012 | 7 | 0.440 |
Why?
|
| Motor Activity | 1 | 2015 | 369 | 0.430 |
Why?
|
| Genotype | 8 | 2017 | 405 | 0.410 |
Why?
|
| Alleles | 4 | 2016 | 224 | 0.400 |
Why?
|
| Obesity | 1 | 2014 | 291 | 0.400 |
Why?
|
| Linear Models | 3 | 2016 | 254 | 0.390 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 144 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 402 | 0.350 |
Why?
|
| Odds Ratio | 5 | 2017 | 285 | 0.350 |
Why?
|
| Cohort Studies | 11 | 2016 | 1939 | 0.340 |
Why?
|
| HIV Infections | 1 | 2014 | 970 | 0.300 |
Why?
|
| Molecular Structure | 4 | 2015 | 28 | 0.290 |
Why?
|
| Interviews as Topic | 3 | 2015 | 130 | 0.290 |
Why?
|
| Receptors, Immunologic | 2 | 2017 | 34 | 0.280 |
Why?
|
| Laryngoscopes | 2 | 2016 | 7 | 0.280 |
Why?
|
| Membrane Glycoproteins | 2 | 2017 | 101 | 0.270 |
Why?
|
| Gold | 2 | 2015 | 5 | 0.270 |
Why?
|
| Methane | 2 | 2015 | 4 | 0.270 |
Why?
|
| Computer Simulation | 3 | 2017 | 218 | 0.260 |
Why?
|
| Small Molecule Libraries | 2 | 2015 | 4 | 0.250 |
Why?
|
| Models, Molecular | 3 | 2016 | 81 | 0.250 |
Why?
|
| Computational Biology | 2 | 2014 | 23 | 0.250 |
Why?
|
| Prevalence | 3 | 2015 | 487 | 0.250 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 2 | 2013 | 15 | 0.240 |
Why?
|
| Stereoisomerism | 2 | 2013 | 10 | 0.230 |
Why?
|
| Forecasting | 2 | 2014 | 117 | 0.230 |
Why?
|
| Molecular Conformation | 2 | 2013 | 15 | 0.230 |
Why?
|
| Cyclization | 2 | 2012 | 2 | 0.220 |
Why?
|
| Middle Aged | 12 | 2017 | 9823 | 0.220 |
Why?
|
| Quantitative Trait Loci | 3 | 2017 | 61 | 0.220 |
Why?
|
| Disabled Persons | 2 | 2016 | 127 | 0.220 |
Why?
|
| Health Status Disparities | 2 | 2013 | 69 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 2 | 2015 | 132 | 0.210 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 86 | 0.210 |
Why?
|
| Confidence Intervals | 2 | 2017 | 96 | 0.180 |
Why?
|
| Laryngoscopy | 2 | 2016 | 21 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 75 | 0.180 |
Why?
|
| Hypoglycemic Agents | 2 | 2016 | 56 | 0.170 |
Why?
|
| Microglia | 2 | 2017 | 124 | 0.170 |
Why?
|
| Logistic Models | 3 | 2015 | 407 | 0.170 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 1184 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 959 | 0.160 |
Why?
|
| Models, Genetic | 2 | 2015 | 35 | 0.160 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 9 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2015 | 124 | 0.160 |
Why?
|
| Reimbursement Mechanisms | 1 | 2017 | 13 | 0.160 |
Why?
|
| Polypharmacology | 1 | 2017 | 1 | 0.150 |
Why?
|
| Instinct | 1 | 2017 | 1 | 0.150 |
Why?
|
| Escape Reaction | 1 | 2017 | 2 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2017 | 13 | 0.150 |
Why?
|
| Crystallography, X-Ray | 2 | 2016 | 14 | 0.150 |
Why?
|
| Spatial Learning | 1 | 2017 | 7 | 0.150 |
Why?
|
| Phenotype | 5 | 2017 | 355 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 2017 | 20 | 0.150 |
Why?
|
| Birth Order | 1 | 2016 | 2 | 0.150 |
Why?
|
| Parity | 1 | 2016 | 4 | 0.150 |
Why?
|
| Reproductive Behavior | 1 | 2016 | 3 | 0.150 |
Why?
|
| Reproduction | 1 | 2016 | 12 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2017 | 90 | 0.150 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 340 | 0.150 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2016 | 80 | 0.140 |
Why?
|
| Substrate Specificity | 2 | 2016 | 26 | 0.140 |
Why?
|
| Walking Speed | 1 | 2017 | 41 | 0.140 |
Why?
|
| Mental Status Schedule | 1 | 2016 | 113 | 0.140 |
Why?
|
| Behavior, Animal | 1 | 2017 | 105 | 0.140 |
Why?
|
| Vehicle Emissions | 1 | 2016 | 2 | 0.140 |
Why?
|
| Receptor, Muscarinic M4 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2016 | 1 | 0.140 |
Why?
|
| Conservation of Natural Resources | 1 | 2016 | 4 | 0.140 |
Why?
|
| Medicare | 2 | 2014 | 121 | 0.140 |
Why?
|
| Policy Making | 1 | 2016 | 15 | 0.140 |
Why?
|
| Neuroticism | 1 | 2016 | 33 | 0.140 |
Why?
|
| Air Pollution | 1 | 2016 | 17 | 0.140 |
Why?
|
| Ecosystem | 2 | 2016 | 27 | 0.140 |
Why?
|
| Hand Strength | 1 | 2016 | 59 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 218 | 0.140 |
Why?
|
| Students, Medical | 1 | 2016 | 46 | 0.140 |
Why?
|
| Employment | 1 | 2016 | 42 | 0.140 |
Why?
|
| Body Size | 1 | 2015 | 11 | 0.140 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2015 | 8 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2014 | 330 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2016 | 91 | 0.130 |
Why?
|
| Ribosomes | 1 | 2015 | 3 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2016 | 127 | 0.130 |
Why?
|
| Acenaphthenes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Trust | 1 | 2015 | 16 | 0.130 |
Why?
|
| Adult | 7 | 2016 | 8601 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 47 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2014 | 3273 | 0.130 |
Why?
|
| Atlanto-Axial Joint | 1 | 2014 | 18 | 0.130 |
Why?
|
| South Africa | 1 | 2014 | 17 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2014 | 20 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 33 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 20 | 0.130 |
Why?
|
| Proteins | 1 | 2015 | 72 | 0.130 |
Why?
|
| Longevity | 1 | 2014 | 32 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2014 | 150 | 0.120 |
Why?
|
| Spinal Fractures | 1 | 2014 | 60 | 0.120 |
Why?
|
| Risk | 1 | 2015 | 217 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2016 | 230 | 0.120 |
Why?
|
| Intelligence Tests | 1 | 2014 | 15 | 0.120 |
Why?
|
| Interview, Psychological | 1 | 2014 | 36 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2014 | 159 | 0.120 |
Why?
|
| Probability | 1 | 2014 | 94 | 0.120 |
Why?
|
| Viral Load | 1 | 2014 | 197 | 0.120 |
Why?
|
| Transcriptome | 1 | 2014 | 83 | 0.120 |
Why?
|
| Movement | 1 | 2014 | 143 | 0.120 |
Why?
|
| Leukemia Virus, Murine | 1 | 2013 | 2 | 0.120 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 13 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2013 | 18 | 0.120 |
Why?
|
| Luminescent Proteins | 1 | 2013 | 9 | 0.120 |
Why?
|
| Genes, Reporter | 1 | 2013 | 30 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2014 | 77 | 0.120 |
Why?
|
| Overweight | 1 | 2014 | 65 | 0.120 |
Why?
|
| Memory | 1 | 2015 | 318 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 152 | 0.120 |
Why?
|
| Religion and Psychology | 1 | 2013 | 24 | 0.120 |
Why?
|
| Cerebral Cortex | 1 | 2015 | 195 | 0.110 |
Why?
|
| Esters | 1 | 2012 | 1 | 0.110 |
Why?
|
| Alkylation | 1 | 2012 | 1 | 0.110 |
Why?
|
| Hemeproteins | 1 | 2012 | 1 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2013 | 99 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2013 | 47 | 0.110 |
Why?
|
| White Matter | 1 | 2015 | 149 | 0.110 |
Why?
|
| Age of Onset | 4 | 2014 | 108 | 0.110 |
Why?
|
| Macrophage Activation | 1 | 2012 | 13 | 0.110 |
Why?
|
| Life Change Events | 1 | 2012 | 36 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 553 | 0.110 |
Why?
|
| Gait | 1 | 2017 | 404 | 0.110 |
Why?
|
| Brain | 4 | 2016 | 1689 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 343 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 328 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 284 | 0.110 |
Why?
|
| Monocytes | 1 | 2013 | 116 | 0.110 |
Why?
|
| Environmental Policy | 1 | 2012 | 2 | 0.110 |
Why?
|
| Air | 1 | 2012 | 6 | 0.110 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 1 | 0.110 |
Why?
|
| Spirituality | 1 | 2013 | 66 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2012 | 6 | 0.110 |
Why?
|
| Anomie | 1 | 2012 | 4 | 0.110 |
Why?
|
| Schistosoma mansoni | 1 | 2012 | 42 | 0.110 |
Why?
|
| Receptors, Complement | 1 | 2012 | 5 | 0.110 |
Why?
|
| Temperature | 1 | 2012 | 76 | 0.110 |
Why?
|
| Life Style | 1 | 2014 | 211 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 59 | 0.110 |
Why?
|
| Diet, Mediterranean | 1 | 2013 | 62 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2013 | 100 | 0.110 |
Why?
|
| Macrophages | 1 | 2012 | 128 | 0.100 |
Why?
|
| Social Environment | 1 | 2012 | 79 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2012 | 97 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2013 | 294 | 0.100 |
Why?
|
| Age Factors | 4 | 2015 | 843 | 0.100 |
Why?
|
| Community Health Planning | 1 | 2011 | 21 | 0.100 |
Why?
|
| Decision Making | 1 | 2012 | 220 | 0.090 |
Why?
|
| Hypertension | 1 | 2012 | 266 | 0.090 |
Why?
|
| Animals | 5 | 2017 | 4552 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 324 | 0.090 |
Why?
|
| Parkinson Disease | 2 | 2016 | 1164 | 0.080 |
Why?
|
| Plaque, Amyloid | 3 | 2015 | 144 | 0.080 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 47 | 0.070 |
Why?
|
| Mice | 3 | 2017 | 1607 | 0.070 |
Why?
|
| Protein Interaction Maps | 2 | 2017 | 17 | 0.070 |
Why?
|
| Ligands | 2 | 2015 | 55 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2017 | 75 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2015 | 70 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2017 | 638 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 432 | 0.060 |
Why?
|
| Haplotypes | 2 | 2012 | 61 | 0.050 |
Why?
|
| Young Adult | 2 | 2016 | 1932 | 0.040 |
Why?
|
| Exome | 1 | 2017 | 8 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 45 | 0.040 |
Why?
|
| Benzazepines | 1 | 2017 | 8 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2017 | 44 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 193 | 0.040 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Acoustic Stimulation | 1 | 2017 | 47 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 17 | 0.040 |
Why?
|
| Maternal Age | 1 | 2016 | 15 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 12 | 0.040 |
Why?
|
| Fertility | 1 | 2016 | 20 | 0.040 |
Why?
|
| Manikins | 1 | 2016 | 6 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 6 | 0.040 |
Why?
|
| Imidazoles | 1 | 2017 | 72 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 153 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 18 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 48 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 78 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 4 | 0.040 |
Why?
|
| Allosteric Site | 1 | 2016 | 1 | 0.040 |
Why?
|
| Nicotinic Acids | 1 | 2016 | 3 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2016 | 5 | 0.040 |
Why?
|
| Crystallization | 1 | 2016 | 5 | 0.040 |
Why?
|
| Tiotropium Bromide | 1 | 2016 | 2 | 0.040 |
Why?
|
| Appalachian Region | 1 | 2016 | 1 | 0.040 |
Why?
|
| Drug Inverse Agonism | 1 | 2016 | 2 | 0.040 |
Why?
|
| Acetylcholine | 1 | 2016 | 12 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2016 | 15 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2017 | 81 | 0.040 |
Why?
|
| Thiophenes | 1 | 2016 | 13 | 0.040 |
Why?
|
| Air Pollutants | 1 | 2016 | 12 | 0.040 |
Why?
|
| Static Electricity | 1 | 2016 | 45 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 1 | 2015 | 7 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 74 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 185 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2015 | 16 | 0.030 |
Why?
|
| Surface Properties | 1 | 2016 | 144 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 52 | 0.030 |
Why?
|
| Zebrafish | 1 | 2015 | 21 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2016 | 77 | 0.030 |
Why?
|
| Acetamides | 1 | 2015 | 7 | 0.030 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 17 | 0.030 |
Why?
|
| Pregnancy | 1 | 2016 | 403 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2015 | 12 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 7 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 2 | 0.030 |
Why?
|
| Coordination Complexes | 1 | 2015 | 2 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Nanofibers | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 30 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 41 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 17 | 0.030 |
Why?
|
| Head Movements | 1 | 2014 | 7 | 0.030 |
Why?
|
| Odontoid Process | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 75 | 0.030 |
Why?
|
| Rats | 1 | 2017 | 854 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2014 | 11 | 0.030 |
Why?
|
| Receptors, Kainic Acid | 1 | 2014 | 3 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 39 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2014 | 6 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 169 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 40 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 132 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 103 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2014 | 82 | 0.030 |
Why?
|
| Exons | 1 | 2013 | 34 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 2015 | 181 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2013 | 25 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 61 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 53 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2014 | 103 | 0.030 |
Why?
|
| Virus Integration | 1 | 2013 | 9 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 73 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 227 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 264 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2014 | 105 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 788 | 0.030 |
Why?
|
| Stem Cells | 1 | 2014 | 46 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 100 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 35 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 3 | 0.030 |
Why?
|
| Dextrans | 1 | 2013 | 5 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2013 | 60 | 0.030 |
Why?
|
| Cadaver | 1 | 2014 | 359 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 56 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2013 | 64 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2013 | 41 | 0.030 |
Why?
|
| Thiazoles | 1 | 2013 | 35 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2013 | 19 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 78 | 0.030 |
Why?
|
| Ovum | 1 | 2012 | 4 | 0.030 |
Why?
|
| Schistosomiasis | 1 | 2012 | 8 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2012 | 27 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2013 | 39 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2012 | 35 | 0.030 |
Why?
|
| Phagocytes | 1 | 2012 | 23 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2014 | 195 | 0.030 |
Why?
|
| Apoptosis | 1 | 2014 | 251 | 0.030 |
Why?
|
| Receptor, EphA1 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 298 | 0.030 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2012 | 7 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2012 | 39 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2012 | 8 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2012 | 21 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2013 | 195 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2014 | 482 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2013 | 136 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2013 | 152 | 0.030 |
Why?
|
| Self Report | 1 | 2013 | 218 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 88 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 321 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 85 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 75 | 0.030 |
Why?
|
| Liver | 1 | 2012 | 173 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2012 | 238 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 343 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 295 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 349 | 0.020 |
Why?
|
| Cytokines | 1 | 2012 | 347 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 679 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1113 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1221 | 0.020 |
Why?
|